Category Archives: pancreatic cancer

Subtypes of Pancreatic Cancer

In the third part of this series on pancreatic cancer, we’ll take a look at recent developments in identifying subtypes of pancreatic cancer and its potential impact on the lives of pancreatic cancer patients. Twenty-one years ago, we had identified … Continue reading

Posted in Cancer Research, pancreatic cancer | Tagged | Leave a comment

The Genetics of Pancreatic Cancer

In the second part of this series on pancreatic cancer, we’ll look at the changes in our understanding of the role of familial genetics in pancreatic cancer, and how that new understanding holds promise for new therapeutics. In the mid-1970s … Continue reading

Posted in Cancer Research, pancreatic cancer | Leave a comment

 Remember, Remember…

A look at our changing understanding of the genetics of pancreatic cancer, and the genomic technologies that helped us gain that understanding over the past 21 years. Continue reading

Posted in Cancer Research, pancreatic cancer | Tagged , , | Leave a comment

Drug Target Identification: And then a miracle occurs

At the front end of most drug discovery programs lies a step called Target Identification, and a few months ago I sat down with a colleague to discuss their approach to target identification.  In particular, “how do you characterize a target”? … Continue reading

Posted in Bioinformatics, Cancer Research, Drug Development, Informatics, pancreatic cancer, Science Blogging | Leave a comment

Merrimack’s New Pancreatic Cancer Drug

The intertubes have been abuzz lately with the news of Merrimack’s results from their Phase III trial of a new triplet therapy for pancreatic cancer.  The triplet combines older standard of care drugs like 5FU and leucovorin with their new … Continue reading

Posted in Drug Development, pancreatic cancer | Tagged , | Leave a comment

Promising Preclinical Results in Pancreatic Cancer

A recent announcement at the AACRs-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19–23, points to some promising results in recent trials that targeted multiple pathways downstream of KRAS (including PI3K/AKT, RAF/MEK/ERK and RAL).  The studies conducted … Continue reading

Posted in Cancer Research, Drug Development, pancreatic cancer | Tagged , , , | Leave a comment

Cui Bono? Finding Super Responders In Clinical Trials

I’m a voracious reader of mysteries in my spare time.  And some juncture in every story, as the detective finds himself staring at the corpse, they ask the inevitable question “Cui Bono — who benefits?”  Oddly enough, this is a … Continue reading

Posted in Cancer Research, Drug Development, Informatics, pancreatic cancer | Tagged , , | Leave a comment